In the management of neurological diseases, the identification and quantification of axonal damage could allow for the improvement of diagnostic accuracy and prognostic assessment.
Abstract
In the management of neurological diseases, the identification and quantification of axonal damage could allow for the improvement of diagnostic accuracy and prognostic assessment.
Neurofilament light chain (NfL) is a neuronal cytoplasmic protein highly expressed in large caliber myelinated axons. Its levels increase in cerebrospinal fluid (CSF) and blood proportionally to the degree of axonal damage in a variety of neurological disorders, including inflammatory, neurodegenerative, traumatic and cerebrovascular diseases. New immunoassays able to detect biomarkers at ultra-low levels have allowed for the measurement of NfL in blood, thus making it possible to easily and repeatedly measure NfL for monitoring diseases' courses.
Evidence that both CSF and blood NfL may serve as diagnostic, prognostic and monitoring biomarkers in neurological diseases is progressively increasing, and NfL is one of the most promising biomarkers to be used in clinical and research setting in the next future. Here we review most important results on CSF and blood NfL and we discuss its potential applications and future directions.
Introduction
In the management of neurological diseases, there is a compelling need for reliable biomarkers that can improve the accuracy of differential diagnosis and of prognostic assessment as well as predict the response to treatments. This applies to central nervous system (CNS) disorders of all causes, including inflammatory, neurodegenerative, traumatic and vascular diseases.
Another application for biomarkers in neurological diseases could be to identify or rule out the presence of neurodegenerative processes, which would be useful for subsequent clinical management.
In CNS and peripheral nervous system diseases associated with axonal injury or degeneration, the concentration of neurofilament light chain (NfL) has been found to increase in cerebrospinal fluid (CSF) and blood. [1] [S1] Over the last two decades, an increasing number of studies have shown that NfL levels in the CSF and blood are altered in CNS diseases and are correlated with the disease characteristics. Furthermore, as a quantitative measure of the ongoing axonal injury, the increase in NfL levels could have a prognostic value in a variety of neurological diseases. Since it is feasible to measure NfL concentration in the blood, it may be a promising biomarker for monitoring the disease course in CNS disorders and, ideally, for evaluating patients' response to treatments.
In this paper, we provide a brief overview of the structure, function, and mechanisms of release of NfL, and the methods by which NfL concentration can be measured. We then review its potential diagnostic and prognostic value in a variety of CNS diseases, as well as its usefulness in monitoring response to treatment, and we discuss how NfL could be applied in clinical practice.
NfL in the diagnostic work-up of multiple sclerosis
The CSF NfL concentration is increased both in MS and in its first clinical presentation, that is, clinically isolated syndrome (CIS). [4] In both these conditions, CSF NfL can be used to identify patients from controls without neurological diseases with high accuracy (area under the curve [AUC] = 0.83 for CIS versus controls; AUC = 0.90 for MS versus controls; no further details available). [4] Similar findings have been reported for serum NfL as well. [2] The timing of NfL measurement could influence its concentration, especially in relation to the time point of the last acute inflammatory episode. Indeed, CSF and serum NfL tend to be higher in relapsing-remitting MS (RRMS) patients with a recent relapse (no longer than 60 days before) than in clinically stable RRMS patients. [5] It is plausible that CSF NfL remains high for 23 months after a relapse and then drops to lower levels.
[S7] Therefore, CSF NfL could have the highest diagnostic accuracy within three months from the last relapse. This probably applies to blood NfL as well, whose concentration seems to follow the same dynamics as CSF NfL. [2] When considering the potential diagnostic applications of NfL in MS, it should be noted that the ability of CSF and blood NfL to discriminate MS from MS mimics has been reported in only a few studies, which have shown conflicting results.[S8,S9] For instance, while one study showed that the CSF NfL concentration was higher in neuromyelitis optica than in MS (no information is available on the diagnostic accuracy),[S10] this was not found to be true for serum NfL. [6] Furthermore, both CSF and serum NfL have been found to be increased in patients with white matter hyperintensity due to cerebral small vessel disease, which is one of the most common differential diagnoses of MS.[S11,S12]
The lack of disease specificity and anatomical characterization of NfL indicates that its CSF and blood measurement cannot replace magnetic resonance imaging (MRI) in the diagnosis of MS and CIS and in the exclusion of MS mimics. Nevertheless, NfL measurement during the diagnostic work-up of CIS and MS patients may still be useful for predicting disease prognosis, as discussed above and in the section on NfL in the monitoring and prognostic evaluation of MS.
NfL in the diagnostic work-up of Alzheimer's disease and frontotemporal dementia
In AD patients, CSF and blood NfL are higher than in HCs. [7] AD patients can be differentiated from HCs with good accuracy in the case of CSF NfL (AUC up to 0.77, 95% CI 0.64-0.89). [8] Similarly, blood NfL showed excellent accuracy (AUC = 0.87; no further details available). [7] In addition, NfL changes in blood appear to precede the first clinical manifestations of AD by about 16 years, as demonstrated by longitudinal studies on AD mutation carriers.
[S13] In this same population, moreover, a peak in the rate of increase of blood NfL has been observed near with the onset of symptoms, thus suggesting that NfL marks onset and intensity of neurodegeneration in AD.[S13,S14]
As a marker of ongoing neuronal damage in AD, one might wonder what the benefit of CSF NfL over CSF total tau (t-tau) can be, even in the context of the recently proposed biological definition of the disease.
[S15] To this regard, while CSF t-tau values seem to reflect amyloiddependent neurodegeneration or increased tau secretion from amyloid-affected neurons, CSF NfL might be a measure of both amyloid-dependent and -independent neuronal loss, [9] which is particularly relevant if considering the contribution of different proteinopathies, vascular disease and neuroinflammation (the so-called mixed pathology) in AD pathophysiology.
[S16]
CSF NfL is also increased in FTD patients as compared to cognitively normal controls (AUC = 0.93, 95% CI 0.90-0.97), [10] and a similar difference has been reported for serum NfL (84% sensitivity and 96% specificity). [11] In terms of the potential clinical applications of CSF or serum NfL, the differences between AD or FTD patients and HCs imply that this biomarker may help in the differential diagnosis between neurodegenerative dementias and non-neurodegenerative disease-mimics (i.e. depression). [1] For instance, it could be difficult to distinguish between the behavioural variant of FTD (bvFTD) and psychiatric disorders in cases where neuroimaging does not reveal frontotemporal atrophy or hypometabolism. In such cases, CSF NfL can help in distinguishing FTD from psychiatric diseases with excellent accuracy (AUC = 0.93, 95% CI 0.85-1.00, p < 0.001).
[S17] Although this finding needs to be confirmed with further investigations, it implies that NfL could be used to rule out neurodegenerative diseases in patients with psychiatric disturbances.
In addition, it would be interesting to investigate whether CSF and blood NfL can be used to identify patients with neurodegenerative diseases among individuals with subjective memory complaints; this could guide clinicians to further proceed with the diagnostic work-up. In this sense, CSF or blood NfL measurement may be useful as a first-line test, i.e. as a screening test, for AD and other neurodegenerative diseases. While NfL changes in CSF might be more sensitive in identifying a neurodegenerative process in its earliest stages, blood NfL measurement would be more feasible as a screening test, due to its lower invasiveness.
A recent study on a population of cognitively healthy individuals has shown that higher CSF NfL values are associated with a three-fold higher risk of mild cognitive impairment (MCI) over a median follow-up of 3.8 years (hazard ratio = 3.13, 95% CI 1.36-7.18 for the top quartile of CSF NfL vs. the bottom quartile; p = 0.01). [12] Interestingly, CSF t-tau, phosphorylated tau (p-tau) and neurogranin were not found to have a similar potential as predictors of MCI. [12] NfL might additionally be useful for better discrimination between AD and FTD. Indeed, in AD (including early-onset forms), the increase in CSF NfL is less pronounced than in FTD,
[S18] and it discriminates between the two disorders with good accuracy (AUC = 0.80, 82% sensitivity, 70% specificity). [13] These results have also been recently replicated in patients with autopsy-confirmed AD and FTD, thus strengthening the evidence on the potential utility of NfL for the differential diagnosis between these two disorders. for t-tau/A42 ratio). [14] CSF NfL could also serve as a biomarker for the differential diagnosis between non-fluent and semantic variant PPAs (nfvPPA and svPPA) and logopenic variant PPA (lvPPA), since it is higher in nfvPPA/svPPA compared to lvPPA (AUC = 0.87, 95% CI 0.79 -0.96, p < 0.0001). [15] Serum NfL also is higher in nfvPPA/svPPA vs lvPPA, although in such comparison its accuracy is lower than CSF NfL (AUC = 0.77, 95% CI 0.65-0.89, p < 0.001). [15] Since NfL seems to lack disease specificity, it cannot be used alone to discriminate between AD and FTD in a clinical setting. However, the addition of NfL to other fluid biomarkers can increase the sensitivity and diagnostic accuracy of the measurements. For instance, while CSF Aβ42 and p-tau were found to be useful for discriminating between early-onset AD and FTD with an AUC of 0.89 (75% sensitivity, 94% specificity), by adding CSF NfL an increase in AUC to 0.92 (86% sensitivity, 100% specificity) was obtained. [13] Another application of NfL in this field might be the differential diagnosis between rapidly progressive dementias and prion diseases, since in these latter NfL hugely increases in the CSF and blood, much more than in AD and other forms of dementia. [16, 17] CSF NfL seems to accurately distinguish prion diseases from atypical or rapidly progressive neurodegenerative dementias (AUC = 0.84 ± 0.04, 85.5% sensitivity, 75% specificity) and from atypical or rapidly progressive AD (AUC = 0.95 ± 0.02, 86.4% sensitivity, 91.9% specificity), with the highest accuracy obtained when NfL is combined with CSF p-tau (AUC for the NfL/p-tau ratio = 0.99 ± 0.007, 92.9% sensitivity, 97.3% specificity). [18] NfL in the diagnostic work-up of amyotrophic lateral sclerosis CSF NfL is higher in patients with ALS compared to healthy and neurological controls,[S5] as well as to patients with other motor neuron diseases (MNDs) (i.e. primary lateral sclerosis, spinal muscular atrophy and Kennedy disease), [19] and ALS mimics (i.e. chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, and cervical myeloradiculopathy). [3] CSF NfL exhibits the highest accuracy (AUC = 0.99, sensitivity 97%, specificity 95%, p < 0.0001) in distinguishing ALS patients from HCs, [20] but its accuracy in distinguishing ALS patients in the early symptomatic phase (onset within six months) from other neurological diseases (AUC = 0.95, 95% CI 0.91-0.99), and ALS mimics (AUC = 0.94, 95% CI 0.94-1.00) is still high. [19] These results are highly relevant, since they provide evidence that NfL may have diagnostic utility even during the first clinical assessment of patients with suspected MND. Moreover, in ALS, CSF and serum NfL have shown to be strongly correlated (r = 0.78, p < 0.0001). [20] The same correlation was found to be weaker in HCs (r = 0.57, p < 0.01), thus leading to hypothesize that ongoing axonal injury with higher CSF NfL in ALS compared to HCs may be associated with a more rapid redistribution of NfL through the blood-brain barrier from CSF to blood. [20] Given the high correlation between CSF and serum NfL in ALS, blood NfL has shown an excellent accuracy (AUC = 0.99; 95% CI 0.97-1.00) for differentiating between early symptomatic ALS and ALS mimics. [19] Recently, a serum NfL cut-off value of 62 pg/mL was found to have a sensitivity of 85.5% (95% CI 78-91.2%) and a specificity of 81.8% (95% CI 74.9-87.4%) in distinguishing ALS from other neurological disorders. [21] Of note, in asymptomatic ALS mutations carriers, no difference has been found in CSF NfL values compared to HCs, while a sharp increase of CSF NfL was described in symptomatic ALS mutations carriers, thus suggesting that, in these patients, NfL could also serve as a marker of disease-onset. [22] In these patients, when longitudinally assessing serum NfL, elevated levels were found in asymptomatic ALS mutations carriers who later developed ALS as far back as 11.6 months before phenoconversion. In addition, serum NfL levels continued to increase in the first six months after symptom onset. On the contrary, in ALS patients serum NfL were found to be substantially stable over a median time of one year. [ In conclusion, CSF and serum NfL have shown excellent diagnostic accuracy for ALS, even in the early phases of the disease. These promising results call for assay standardization and validation, as discussed further below, before NfL could be used in the clinical practice.
NfL in the diagnostic work-up of parkinsonian and movement disorders
In Parkinson's disease (PD) patients, it seems that the NfL levels in CSF do not increase, as it has repeatedly been reported that the levels are similar to those in HCs. [24] On the contrary, CSF NfL is reportedly increased in patients with progressive supranuclear palsy (PSP), multiple system atrophy (MSA), and corticobasal syndrome (CBS) as compared to HCs and to PD patients as well. [24] Among APDs patients, CSF and blood NfL are higher in PSP than in MSA patients.[S4,S47] Further, CSF NfL can be used to differentiate between PD and APDs with high diagnostic accuracy (AUC = 0.82, 75% sensitivity, 83% specificity for PSP vs. PD, AUC = 0.94, 80% sensitivity, 96.9% specificity for MSA vs. PD), [25, 26] and blood NfL exhibits similar diagnostic performance. [27] Finally, patients with DLB and PDD seem to have lower CSF NfL values than MSA, PSP and CBS patients, [28] as well as patients with other neurodegenerative dementias, e.g. FTD and late-onset AD. [29] While CSF NfL alone is not adequate for distinguishing between DLB and AD (AUC = 0.53, 33% sensitivity, 82% specificity), [13] the addition of CSF Aβ42, p-tau and α-synuclein improves the diagnostic accuracy (AUC = 0.90, 95% CI 0.85-0.96, 90% sensitivity, 81% specificity). [28] Finally In conclusion, either CSF or blood NfL could be useful for the differential diagnosis of PD and APDs. Since evidence for the diagnostic value of NfL can be found only in studies performed on patients with an established diagnosis, CSF or blood NfL would be more appropriate as a supplementary measurement to help movement disorder specialists in the differential diagnosis between PD and APDs.
NfL in the diagnostic work-up of traumatic brain injury
CSF and blood NfL concentrations are found to be increased after TBI. Studies on TBI provide a good understanding of the dynamics of NfL from the brain to the periphery after acute axonal damage. In the first two weeks following severe TBI, NfL sharply increases in both CSF and blood as compared to patients with other neurological diseases and HCs. [30] Within one year of severe TBI, the blood NfL level normalizes, but no information is available about its levels between the acute phase and after one year. [30] Studies on mild TBI mainly focus on athletes engaged in contact sports. Boxers have higher CSF and serum NfL concentrations than non-boxers, especially after a bout with ≥15 hits. [31] CSF NfL does not peak immediately after a bout, but it peaks after 15 days and normalizes after 39 months. [32] In contrast, soccer headings in amateur players do not seem to result in an increase in the CSF NfL values, according to measurements obtained 710 days after a heading training session. [33] Similar to TBI, in a few studies traumatic spinal cord injury (TSCI) has been associated to an increase of NfL values in both CSF, [34] and blood. [5] Based on the findings so far, it seems that further studies are required to define the dynamics of blood NfL after a head trauma and, therefore, the best timing for its measurement. It is also not clear whether NfL measurement would be beneficial for the comprehensive management of TBI.
[S24] A potential clinical utility of this biomarker would be to help clinicians in deciding whether a patient with TBI has to undergo a head CT or MRI. In one study, it has been shown that blood NfL can be used to accurately identify patients with abnormal head CT findings after a head trauma (AUC = 0.84, 95% CI 0.77-0.92). [35] Further investigations in which different diagnostic modalities (i.e. blood NfL, EEG, and head CT or MRI scan) are compared are therefore recommended.
Association of NfL with disease characteristics and its potential prognostic value
There would be two prognostic uses of NfL: as a baseline measure at disease onset or diagnosis, and as a longitudinal and repetitive measure. Its repeated measurement may be applicable to patient monitoring in clinical practice as well as in clinical trials. The ability of NfL to reflect the degree of axonal damage makes it a reliable marker of disease intensity and/or activity across a range of CNS diseases.
[S2] The potential correlation of both CSF and blood NfL with specific disease characteristics has been widely investigated (Table 1) . Furthermore, the potential value of baseline and/or longitudinal measurements of CSF and blood NfL in predicting the course of different neurological diseases, i.e. MS, AD, FTD, ALS, APDs and TBI, has also been verified.
NfL levels in both CSF and blood have been shown to be additional independent prognostic factors in a variety of neurological disorders, thus confirming their potential to contribute to existing prognostic factors.
NfL in the monitoring and prognostic evaluation of multiple sclerosis
MS monitoring is nowadays largely dependent on serial MRI, but this is limited by several factors, including the high frequency of gadolinium administration and difficulties in precisely registering serial MRI scans. In addition, it is difficult to image the spinal cord longitudinally.
Given this situation, a CSF or blood test may provide an alternative or complementary option for monitoring MS disease activity over time.
Overall, it has been found a trend towards a reduction of serum NfL values over time in CIS and RRMS patients, which was significant relative to baseline at month 6 (p = 0.008), 12 (p = 0.001) and 24 (p = 0.007). [36] Since in that study patients had active disease at baseline, such reduction could be interpreted as a possible regression to the mean. Also, these patients were started on a DMT after the baseline, and this could have contributed to the decrease over time of serum NfL. [36] CSF and serum NfL have been tested as indicators of disease activity (defined by a clinical relapse occurred within 3 months before sampling or by the presence of Gd+ lesions in MRI scans performed within 6 weeks before sampling). CSF NfL shows good accuracy (AUC = 0.77, 95% CI 0.71-0.84, 67% sensitivity, 75% specificity) and serum NfL shows sufficient accuracy (AUC = 0.63, 95% CI 0.59-0.74, 45% sensitivity, 80% specificity) in detecting patients with disease activity. Serum NfL accuracy is improved when it is used as an indicator of new Gd+ lesions (AUC = 0.85, sensitivity 84%, specificity 66%).
[S9]
It has been proposed that blood NfL should be integrated with the current measures to determine the 'no evidence of disease activity' (NEDA) status. [37] Indeed, NfL measurement may provide more information on the degree of ongoing axonal damage in normal-appearing white matter, which is not accurately reflected by standard MRI and relapse rate. [38] The relatively low accuracy of serum NfL in detecting classic disease activity markers (i.e. relapses or Gd+ lesions) means that serial NfL measurement cannot be used alone as a substitute for clinical and MRI monitoring, but rather, it can be used as a supplementary measure for detecting axonal damage. With regard to the potential prognostic applications of NfL, it could be used for the identification of patients with pre-clinical MS (i.e. radiologically isolated syndrome or RIS) or with CIS who are likely to develop MS. It has been found that a higher CSF NfL concentration is an independent risk factor for the development of MS in RIS patients, although it has minor relevance (hazard ratio = 1.03, 95% CI 1.01-1.05 p = 0.003) in comparison to other prognostic markers such as CSF IgG oligoclonal bands (OCB) (hazard ratio = 8.9, 95% CI 1.04-75.6 p = 0.046). [39] The ability of CSF NfL to predict conversion to MS in CIS patients is controversial. While some authors have reported higher CSF NfL values at the baseline in CIS patients who were later diagnosed with MS,[S8] some others have reported contrasting findings. [40] Moreover, even in studies where CSF NfL was found to be an independent risk factor for clinically defined MS development, it was not as relevant as CSF IgG OCB and MRI T2 lesions, with a hazard ratio increase of (i) 1.005, 95% CI 1.000- Also, longitudinal NfL changes have shown a similar prognostic value compared to baseline measurement. For instance, a 10-fold increase in serum NfL over 24 months is associated with a 4.7-fold (95% CI 3.3-6.9, p<0.001) increase in new Gd+ lesions over the same period. [36] Another potential prognostic application of NfL could be for the prediction of disability. CSF and serum NfL at the baseline are independent predictors of Expanded Disability Status Scale (EDSS) scores and Multiple Sclerosis Severity Score (MSSS) at follow-up. [2] [S7]
Longitudinal changes of serum NfL also correlate with EDSS changes over time (a 10-fold increase in serum NfL over 24 months being associated with an EDSS score increase of 0.53 [95% CI 0.14-0.91, p = 0.001] over the same period. [36] In optic neuritis, baseline CSF NfL seems to positively correlate with MSSS assessed after a median time of 13 years (correlation coefficient = 0.41, p = 0.018). [43] Further, CSF NfL was shown to be an independent risk factor for conversion into the secondary progressive phenotype. Indeed, in a retrospective study with a 14-year median follow-up time, it was found that in patients with higher baseline CSF NfL concentrations (> 386 ng/L), conversion from RRMS to secondary progressive MS (SPMS) was more likely than it was in patients with low or intermediated CSF NfL values (< 60 ng/L, p = 0.01; 60-386 ng/L, p = 0.03, respectively). [44] With regard to the prognostic value of blood NfL, the timing of longitudinal measurements is an important issue. Indeed, within two months after CIS, serum NfL does not seem to be dependent from the interval between CIS onset and blood sampling. [40] On the contrary, six months after optic neuritis, CSF NfL shows a median decrease of 45% of its baseline values, but it is retained at higher levels in subjects with poorer visual outcomes.
[S25] Therefore, while the first assessment of NfL can be performed at any time within two months after the first clinical event without expecting any significant variations in its levels, a second measurement six months later could have a more specific prognostic value. follow-up. [7] Another potential application of NfL could be in the monitoring of subjects with genetic risk factors for AD. Indeed, it has been demonstrated that serum NfL correlates with the estimated years to symptom onset in autosomal dominant AD mutations carriers (correlation coefficient = 0.75, p < 0.001 for serum NfL). [45] This finding points to the possibility of evaluating the effects of drugs in subjects with pre-clinical AD in clinical trials.
In FTD patients, higher baseline CSF NfL levels are independently correlated with a worse prognosis and shorter survival. For instance, while the five-year survival of FTD patients with a baseline CSF NfL <1989 pg/mL is 73%, it decreases to 36% when the baseline CSF NfL is >3675 pg/mL (estimated hazard ratio 1.7, 95% CI 1.3-2.1, p < 0.001). [46] Such a prognostic effect is superior to that of CSF p-tau/t-tau (estimated hazard ratio 0.7, 95% CI 0.56-0.86, p = 0.001). [46] In addition, the baseline serum NfL levels seem to correlate with the rate of frontal and parietal lobe atrophy over the year following serum sampling (correlation coefficient = 0.53, p = 0.003 and 0.38, p = 0.04, respectively). [11] CSF NfL has shown a positive correlation with the magnitude of annual MMSE score loss in FTD patients (correlation coefficient = 0.5, p = 0.003). [1] In other studies, CSF and serum NfL did not show a significant association with the progression of cognitive impairment. [11, 47] However, changes over time could have been less detectable in patients with low executive function scores already at the baseline. [11] Finally, since serum NfL correlates with functional impairment and brain atrophy in FTD at different disease stages, [11] NfL has shown to be an independent prognostic marker for ALS. In fact, as mentioned earlier, the CSF and serum NfL concentrations are associated with the number of regions with both UMN and LMN involvement (Table 1) . [3, 50] Also, CSF NfL is predictive of the time to the generalization of motor symptoms (hazard ratio = 7.9, 95% CI 2.9-21.4, p < 0.0001, over about one year of follow-up). [3] Accordingly, higher CSF and blood values are associated with a more rapid progression and shorter overall survival. [3, 49, 51] For instance, patients within the highest tertile of CSF NfL reach a mortality hazard ratio of up to 31.82 (95% CI 3.8 -269.7, p = 0.002), up to 3.82 (95% CI 2 -7.4, p < 0.001) for blood NfL. [20] 
NfL in the prognostic evaluation of parkinsonian and movement disorders
The prognostic value of NfL has been assessed in PD and PSP, but there are no data on its prognostic value in MSA and CBS. In the case of PD, the baseline CSF NfL values associate with the mean change per year in the Dementia Rating Scale scores (correlation coefficient = -0.25, p = 0.03).
[1] Also, they predict the risk of conversion into PDD in the following 59 years (hazard ratio for CSF NfL >1100 pg/mL = up to 2.6, 95% CI 1.1-5.9, p = 0.03), but the prediction model performs better with the addition of other biomarkers, such as CSF Aβ42 (hazard ratio for CSF NfL/Aβ42 ratio >1 = up to 6.7, 95% CI 1.5-30.5, p = 0.01). [25] In PSP, higher baseline CSF and blood NfL values seem to correlate with faster worsening of motor and cognitive symptoms. For instance, patients with baseline plasma NfL levels ≥ 36.7 pg/mL were found to have more severe worsening of the PSP rating scale score (mean increase in score = 36.5%, 95% CI 28.8-44.3%) over one year than patients with baseline plasma NfL levels <36.7 pg/mL (mean increase in score = 28.9%, 95% CI 22-35.9%). 
NfL in the prognostic evaluation of traumatic brain injury
TBI is a risk factor for both short-term (e.g. post-concussion syndrome and post-traumatic epilepsy) and long-term neurological sequelae (e.g. AD and chronic traumatic encephalopathy) but, so far, no reliable prognostic marker for TBI has been discovered. [S24] CSF and serum NfL have been proven to be good prognostic markers that are able to predict the clinical and neuroradiological outcomes. [30, 54] In patients with mild TBI, serum NfL values measured at 1 and 36 h after the trauma can be used to differentiate between patients with rapidly resolving symptoms and patients with In ice hockey players, the baseline CSF NfL seems to be correlated with the number of previous incidents of mild TBI and tends to be higher in players with a history of prolonged postconcussive syndrome.
[S31] In addition, one hour after sport-related TBI, serum NfL was found to be highly accurate for distinguishing between athletes who, after a concussion, returned to play within 10 days and athletes who returned after a longer delay (AUC = 0.82, p < 0.0001). 
Conclusions and future directions
Over the last two decades, CSF and blood NfL have been shown to be reliable biomarkers of axonal damage across a variety of neurological disorders. Even though NfL changes in biofluids are not specific to any particular CNS disease, this biomarker may have diagnostic value and significant potential in terms of prognostic assessment and disease monitoring.
With respect to its diagnostic potential, NfL might be useful for the diagnosis of ALS and for the early identification of presymptomatic ALS mutations carriers who are about to become symptomatic. In addition, NfL might serve for identifying a neurodegenerative process in patients with psychiatric manifestations and, hopefully, in individuals with subjective memory complaints. In these cases, once a neurodegenerative disorder is suspected, NfL, together with other disease-specific biomarkers (e.g. CSF AD core biomarkers) might be especially beneficial for the differential diagnosis between FTD and AD and between prion diseases and rapidly progressive neurodegenerative dementias. Finally, NfL could help clinicians in the differential diagnosis between APDs and PD, in cases with overlapping clinical manifestations.
Even though in MS and in TBI NfL per se does not have any specific diagnostic value, it might still be useful to determine its CSF or serum concentrations during the diagnostic work-up and disease monitoring, since they provide clinicians with an overview of the severity of the ongoing axonal damage, which has important prognostic implications.
As a prognostic marker indeed, NfL may have potential as a predictor of disease activity in MS patients, thus potentially guiding clinicians in the choice of the best DMT, but also as a predictor of cognitive worsening in AD, FTD, and PD and of motor worsening in ALS and APDs patients.
Although there may be many potential contexts of use of NfL, before it can be applied as a biomarker in the clinical setting, there are some steps that need to be undertaken in order to assess the analytical validity and the clinical validity and utility of NfL. One of the limitations to its use is the lack of standard reference materials and methods for NfL measurement both in CSF and blood. Standardization efforts and round robin studies will allow for reliable  Data on the correlation between NfL and clinical outcomes in different neurological disorders, followed-up for a long period of time, are highly needed.
Search strategy and selection criteria.
References for this Review were identified by searches of PubMed between 1990 and January 31 st 2019, and references from relevant articles. The following search terms were used:
"neurofilament light", "neurofilament light chain", "neurofilament light protein", "NfL"; "cerebrospinal fluid", "CSF", "serum", "plasma", "blood"; "demyelinating diseases", "multiple sclerosis", "MS", "clinically isolated syndrome", "CIS", "radiologically isolated syndrome", "RIS", "optic neuritis", "myelitis"; "amyotrophic lateral sclerosis", "ALS", "motor neuron diseases"; "frontotemporal dementia", "frontotemporal lobar degeneration", "FTD", "FTLD", "primary progressive aphasia", "PPA", "Alzheimer's disease", "AD", "mild cognitive impairment", "MCI", "dementia", "Parkinson's disease", "PD", "Parkinson's disease dementia", "PDD", "dementia with Lewy body", "DLB", "progressive supranuclear palsy", "PSP", "multiple system atrophy", "MSA", "corticobasal syndrome", "CBS", "Huntington's disease", "HD", "normal pressure hydrocephalus", "NPH", "HIV", "AIDS", "AIDS dementia complex", "ADC", "antiretroviral therapy", "ART", "Stroke", "transient ischemic attack", "hemorrhage", "subarachnoid hemorrhage", "SAH", "intracerebral hemorrhage", "cardiac arrest", "resuscitation", "autoimmune encephalitis", "paraneoplastic encephalitis". There were no language restrictions. The final reference list was generated based on relevance to the topics covered in this Review. Additional references can be found in the online supplementary file. Large calibre myelinated axons abundantly express neurofilaments (Nfs). Nfs are cylindrical structures of 10 nm calibre and they are exclusively located in neurons. They confer structural stability to the axons, enable the radial growth of the myelinated axons and expand their calibre thus allowing a higher conduction velocity. Nfs are classified as intermediate filaments (IFs), i.e. as filaments with an intermediate diameter (10 nm) between actin (6 nm) and myosin (15 nm). In the central nervous system (CNS), Nfs are made of neurofilament light chain (NfL), neurofilament middle chain (NfM), neurofilament heavy chain (NfH) and α-internexin (α-int). All of these subunits have a conserved α-helical rod domain with a variable amino-terminal and carboxy-terminal region. The length of these latter confers a different molecular weight. NfH has the highest molecular weight and presents, in its tail, a glutamic-acid-rich segment (E segment), multiple lysine-serine-proline (KSP) repeats that are phosphorylated and a lysineglutamic acid-proline (KEP) segment. NfM has a shorter tail with two glutamic-acid-rich segments (E1 and E2 segments), two lysine-serine-proline (KSP) repeats segments and a serine-proline (SP) and lysine-glutamic acid (KE) segment. The tail of NfL is made of the glutamic-acid-rich segment (E segment). Finally, α-int has, in its tail, a glutamic-acid-rich segment (E segment) and a lysine-glutamic acid (KE) segment. 
